2015 Year in Review

In just one year Amgen successfully launched an unprecedented six new products; grew our business, adding new and leveraging legacy products; defended products against our competitors; advanced our pipeline, our biosimilars portfolio and geographic scope; and continued to transform Amgen to reach its full potential and build a better company for the future. Amgen’s CEO Bob Bradway and members of his senior team prepared a summary message for staff members, which is posted below.